Eli Lilly and Company offers the Lilly Oncology Support Center for patients prescribed a Lilly Oncology product. Through the Lilly Oncology Support Center, Lilly strives to offer individualized treatment support for eligible patients prescribed a Lilly Oncology product.
For more information, search the prescribed Lilly oncology product in this Guide, go online, or call 1.866.472.8663, Monday through Friday, 8:00 AM to 10:00 PM EST.
For patients prescribed Verzenio, please call 1.844.837.9364, Monday through Friday, 8:00 AM to 10:00 PM EST.
Oncology-related products: Alimta® (pemetrexed) for injection, Cyramza® (ramucirumab) injection, Erbitux® (cetuximab) injection, Portrazza® (necitumumab) injection, Retevmo™ (selpercatinib) capsules, Verzenio® (abemaciclib) tablets
The Lilly Cares Foundation, Inc., a separate nonprofit organization, offers a patient assistance program to help qualifying patients receive Lilly medications at no cost.
Patients may be eligible for the Lilly Cares program if:
For more information about the Lilly Cares Foundation and to enroll, visit LillyCares.com.
Commercially insured, qualified patients must first pay a portion of their co-pay or coinsurance ($25 for each dose of the prescribed Lilly Oncology medicine). The program will cover the remainder of the patient’s co-pay or coinsurance for the prescribed Lilly Oncology medicine, up to a monthly cap of wholesale acquisition cost plus usual and customary fees and a an annual cap set at Lilly's sole discretion during a 12-month enrollment period.
To be eligible, patients must:
Patients may not be participating in any state or federal healthcare program, including, without limitation, Medicaid, Medicare, Medigap, DoD, VA, TriCare, or any state, patient, or pharmaceutical assistance program; patients who move from commercial insurance to a state or federal healthcare program will no longer be eligible.
To enroll, go online or fax the completed enrollment form to the number listed.
For any questions, call the Lilly Oncology Support Center at 1.866.472.8663, Monday-Friday, 8:00 AM to 10:00 PM EST.
Through the Lilly Oncology Support Center, Lilly strives to offer individualized treatment support for eligible patients prescribed a Lilly Oncology product. For those who qualify, Lilly Oncology can help with reimbursement, including:
For more information, call 1.866.472.8663, Monday through Friday, 8:00 AM to 10:00 PM EST.
If patients cannot afford their co-pay or coinsurance, Lilly Oncology Support Center can provide information about a number of independent patient assistance programs that may be able to help eligible patients. These foundations are not affiliated with Eli Lilly and Company and have been established and are operated independently.
Funding availability changes weekly, so contact a Lilly Oncology Support Center representative at 1.866.472.8663, Monday through Friday, 8:00 AM to 10 PM EST for the most recent updates.
The Retevmo Interim Access Program may provide a temporary supply of Retevmo at no cost to insured, eligible patients who have been prescribed Retevmo for the first time and are experiencing a delay in their insurance coverage decision.
To be eligible, patients must:
This program is not available to patients whose insurers have made a final determination to deny the patient coverage for Retevmo. If a denial is received after the initial five business days have passed and appeal rights are being pursued, or if there is a persistent coverage delay, the patient, under appropriate circumstances, may be eligible for up to three additional 15-day supplies of Retevmo.
To enroll, fax the completed enrollment form to 1.877.427.4030 or call the Lilly Oncology Support Center at 1.866.472.8663, Monday through Friday, 8:00 AM to 10:00 PM EST.
This dose exchange program may simplify midcycle dose changes for patients. It ships the appropriate dose directly to patients’ homes in as early as 48 hours and at no cost to them. Additional terms and conditions apply.
To be eligible for the MyRightDose program, a patient must:
To enroll, fax the completed program-specific enrollment form to 1.844.372.9043. For more information, call 1.833.290.2175, Monday through Friday, 9:00 AM to 6:00 PM EST.
Retevmo Savings & Support can provide insurance and coverage assistance. A benefits investigation helps eligible, enrolled patients understand their coverage options, locate the appropriate specialty pharmacy, and identify their lowest possible out-of-pocket cost, and a field reimbursement manager helps patients access prescribed Lilly FDA-approved medicines.
For more information, call Lilly Oncology Support Center at 1.866.472.8663, Monday through Friday, 8:00 AM to 10:00 PM EST.
Eligible, commercially insured covered patients pay as little as $0 a month. Offer is good for up to 12 months until Dec. 31, 2022. Patients must have coverage for Retevmo through their commercial drug insurance coverage to pay as little as $0 for a 30-day supply of Retevmo. Offer is subject to a monthly cap and a separate annual cap.
Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. Card activation is required.
This offer is invalid for patients without commercial drug insurance or those whose prescription claims for Retevmo are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TriCare/CHAMPUS, or any state patient or pharmaceutical assistance program.
Patients can download the savings card online or call 1.866.472.8663, Monday through Friday, 8:00 AM to 10:00 PM EST to request one.
Once enrolled in the Verzenio Continuous Care Program, patients will have access to a benefits investigation.
The program will help patients understand their coverage options, locate the appropriate pharmacy, and identify their lowest possible out-of-pocket cost.
For any questions, call Lilly Oncology Support Center at 1.844.837.9364, Monday through Friday, 8:00 AM to 10:00 PM EST.
This dose exchange program may simplify midcycle dose reductions for patients and at no cost to them. Additional terms and conditions apply.
To be eligible for the program, patients must:
To enroll, fax the completed the program-specific enrollment form to 1.833.665.6329.
For more information, call 1.833.557.2417, Monday through Friday, 9:00 AM to 6:00 PM EST or visit verzenio.com.
Eligible, commercially insured patients may pay as little as $0 a month. Offer subject to a monthly cap of the wholesale acquisition cost plus usual and customary pharmacy charges and a separate annual cap set at Lilly's sole discretion. Patients are responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps.
This offer is invalid for patients without commercial insurance or whose prescription claims for Verzenio are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TriCare/CHAMPUS, or any state, patient, or pharmaceutical assistance program. Card activation is required.
Digital cards can be downloaded online.
For any questions or to request a savings card, call the Lilly Oncology Support Center at 1.844.837.9364, Monday through Friday, 8:00 AM to 10:00 PM EST.